|
|
 |
|
Viewing report
|
|
|
|
Schering-Plough Corporation: Company Profile and SWOT Analysis
iCD Research, Sep 2011, Pages: 50
Synopsis
ICD Research's 'Schering-Plough Corporation: Company Profile and SWOT Analysis' contains in depth information and data about the company and its operations. The profile contains a company overview, business description, financial ratios, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
Summary
This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.
ICD Research's 'Schering-Plough Corporation: Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about Schering-Plough Corporation for business intelligence requirements
- Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
- Provides analysis on financial ratios of the company
- The profile also contains information on business operations, company history, major products and services, prospects, key competitors, key employees, locations and subsidiaries
Reasons To Buy
- Quickly enhance your understanding of the company
- Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
- Increase business/sales activities by understanding your competitors’ businesses better
- Recognize potential partnerships and suppliers
- Obtain yearly profitability figures
Key Highlights
Schering-Plough Corporation (Schering-Plough) is a pharmaceutical company focused on discovery, development, manufacturing and marketing of medical therapies and treatments. The company has operations across more than 140 countries worldwide. The key therapeutics areas of the company include cardiovascular, respiratory, inflammatory disorders, women’s health and infectious diseases. Schering-Plough commercializes consumer brands in the over-the-counter (OTC), foot care and sun care areas. It also sells live stock, companion animal and poultry products for animal health worldwide. The company is headquartered in New Jersey, the US.
In February 2009, Nobilon, a business unit of Schering-Plough's human vaccine, entered into a licensing agreement with the World Health Organization to provide access of pandemic influenza vaccine manufacturing technology to developing countries. In March 2009, Schering Plough and Merck entered into a merger agreement and after merger, Schering Plough will be combined under the name of Merck. During the same month, the company received European commission and FDA approval for the intravenous formulation of temozolomide as an alternative to the already approved oral form of the drug.
In April 2009, Centocor Ortho Biotech Inc. and Schering-Plough received approval of SIMPONI from Health Canada for the Treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. In July 2009, Schering-Plough K.K. received marketing approval of Twisthaler for the treatment of major depressive disorder and Remeron for the treatment of bronchial asthma in adults in Japan. Recently, in September 2009, the company announced the launch of non-drowsy Claritin 12-Hour, an over-the-counter drug to treat symptoms such as itchy, watery eyes, sneezing, and runny nose.
In September 2009, the company launched the Non-Drowsy Claritin 12-Hour in market in 2009. It is an over-the-counter drug to treat symptoms such as itchy, watery eyes, sneezing, and runny nose. Also, in September 2009, the company reported Vicriviroc data for phase II VICTOR-E1 study which evaluated 85 treatment-experienced HIV-infected patients. It also revealed results of saphris relapse prevention clinical study, in September 2009. In October 2009, the company entered into an agreement with OPKO Health, Inc., whereby OPKO would acquire assets relating to the company's neurokinin-1 receptor antagonist program. Also, in October 2009, the company received approval from the European Union antitrust regulators, relating to its takeover by U.S. drugmaker, Merck & Co Inc.
|
|
|
|
